The decline in Novo Nordisk's stock price is attributed to the company's third-quarter sales falling short of market expectations. This occurred despite the continued growth of its weight-loss drugs, Ozempic and Wegovy, which indicates that other areas of the business may not have performed as well as anticipated. The market's reaction suggests a negative short-term impact on the stock price.